A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RIDE)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Genentech
ClinicalTrials.gov Identifier:
NCT00473382
First received: May 13, 2007
Last updated: August 1, 2013
Last verified: August 2013
Results First Received: November 30, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator);   Primary Purpose: Treatment
Conditions: Diabetes Mellitus
Macular Edema
Interventions: Drug: Ranibizumab
Drug: Sham injection

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Patients were recruited from study sites in the United States, Argentina, Peru, Columbia, Chile, and Peru. There were 47 patients from the Latin American countries.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Ranibizumab 0.3 mg Patients received ranibizumab 0.3 mg monthly administered intravitreally for 36 months.
Ranibizumab 0.5 mg Patients received ranibizumab 0.5 mg monthly administered intravitreally for 36 months.
Sham Injection/Ranibizumab 0.5 mg Patients received a sham intravitreal injection monthly for 24 months. Patients who had not discontinued treatment by Month 24 could choose to receive ranibizumab 0.5 mg monthly administered intravitreally for the subsequent 12 months.

Participant Flow:   Overall Study
    Ranibizumab 0.3 mg     Ranibizumab 0.5 mg     Sham Injection/Ranibizumab 0.5 mg  
STARTED     125     127     130  
COMPLETED     98     98     102  
NOT COMPLETED     27     29     28  
Adverse Event                 1                 1                 3  
Death                 5                 10                 3  
Lost to Follow-up                 3                 3                 3  
Physician Decision                 2                 2                 1  
Subject non-compliance                 2                 1                 5  
Subject needed other treatment                 3                 2                 1  
Subject's decision                 11                 10                 12  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Ranibizumab 0.3 mg Patients randomized to this group received ranibizumab 0.3 mg monthly administered intravitreally for 24 months.
Ranibizumab 0.5 mg Patients randomized to this group received ranibizumab 0.5 mg monthly administered intravitreally for 24 months.
Sham Injection Patients randomized to this group received a sham intravitreal injection monthly for 24 months.
Total Total of all reporting groups

Baseline Measures
    Ranibizumab 0.3 mg     Ranibizumab 0.5 mg     Sham Injection     Total  
Number of Participants  
[units: participants]
  125     127     130     382  
Age  
[units: years]
Mean ± Standard Deviation
  62.7  ± 11.1     61.8  ± 10.1     63.5  ± 10.8     62.7  ± 10.7  
Gender  
[units: participants]
       
Female     52     47     64     163  
Male     73     80     66     219  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Percentage of Patients Who Gained ≥ 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score From Baseline at Month 24   [ Time Frame: Baseline to Month 24 ]

2.  Secondary:   Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Score at Months 24 and 36   [ Time Frame: Baseline to Months 24 and 36 ]

3.  Secondary:   Percentage of Patients With a Visual Acuity (VA) Snellen Equivalent of 20/40 or Better at Months 24 and 36   [ Time Frame: Months 24 and 36 ]

4.  Secondary:   Percentage of Patients Who Lost < 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score From Baseline at Months 24 and 36   [ Time Frame: Baseline to Months 24 and 36 ]

5.  Secondary:   Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Score at Months 24 and 36 in Patients With Focal Edema at Baseline   [ Time Frame: Baseline to Months 24 and 36 ]

6.  Secondary:   Mean Change From Baseline in Central Foveal Thickness at Months 24 and 36   [ Time Frame: Baseline to Months 24 and 36 ]

7.  Secondary:   Percentage of Patients With a ≥ 3-step Worsening From Baseline in the Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale Score for Eyes at Months 24 and 36   [ Time Frame: Baseline to Months 24 and 36 ]

8.  Secondary:   Percentage of Patients With Resolution of Leakage at Month 24   [ Time Frame: Baseline to Month 24 ]

9.  Secondary:   Mean Number of Macular Laser Treatments From Baseline Through Months 24 and 36   [ Time Frame: Baseline to Months 24 and 36 ]

10.  Secondary:   Percentage of Patients Who Gained ≥ 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score From Baseline at Month 36   [ Time Frame: Baseline to Month 36 ]


  Serious Adverse Events


  Other Adverse Events
  Hide Other Adverse Events

Time Frame Adverse events were recorded from the first day of treatment through Month 36.
Additional Description The sham Months 0-36 group includes patients randomized to sham; the majority crossed-over to ranibizumab 0.5 mg in Year 3. The sham Months 0-24 group includes patients who received sham during the first 24 months of the study. Serious adverse events that occurred after early crossover to ranibizumab (defined as prior to Month 25) are not included.

Frequency Threshold
Threshold above which other adverse events are reported   5%  

Reporting Groups
  Description
Ranibizumab 0.3 mg - Months 0-36 Patients received ranibizumab 0.3 mg monthly administered intravitreally for 36 months.
Ranibizumab 0.5 mg - Months 0-36 Patients received ranibizumab 0.5 mg monthly administered intravitreally for 36 months.
Sham Injection/Ranibizumab 0.5 mg - Months 0-36 Patients received a sham intravitreal injection monthly for 24 months. Although still masked, patients who had not discontinued treatment by Month 24 could choose to receive ranibizumab 0.5 mg monthly administered intravitreally for the subsequent 12 months. Data in this column represent the safety data in the sham group during the entire 36 months of the trial; most patients crossed over to receive ranibizumab 0.5 mg monthly in the third year.
Sham Injection - Months 0-24 Patients received a sham intravitreal injection monthly for 24 months. Data in this column represent the safety data in the sham group during the first 24 months of the trial when patients were receiving only sham injections. Safety data shown here are also included in the Sham/Ranibizumab 0.5 mg - Months 0-36 column.

Other Adverse Events
    Ranibizumab 0.3 mg - Months 0-36     Ranibizumab 0.5 mg - Months 0-36     Sham Injection/Ranibizumab 0.5 mg - Months 0-36     Sham Injection - Months 0-24  
Total, other (not including serious) adverse events          
# participants affected / at risk     120/125     121/124     123/127     123/127  
Blood and lymphatic system disorders          
Anaemia † 1        
# participants affected / at risk     13/125 (10.40%)     21/124 (16.94%)     16/127 (12.60%)     13/127 (10.24%)  
Cardiac disorders          
Atrial fibrillation † 1        
# participants affected / at risk     4/125 (3.20%)     4/124 (3.23%)     7/127 (5.51%)     4/127 (3.15%)  
Cardiac failure congestive † 1        
# participants affected / at risk     7/125 (5.60%)     4/124 (3.23%)     8/127 (6.30%)     7/127 (5.51%)  
Coronary artery disease † 1        
# participants affected / at risk     6/125 (4.80%)     4/124 (3.23%)     7/127 (5.51%)     4/127 (3.15%)  
Eye disorders          
Cataract (F) † 1 [3]        
# participants affected / at risk     38/125 (30.40%)     41/124 (33.06%)     31/127 (24.41%)     25/127 (19.69%)  
Cataract (S) † 1 [4]        
# participants affected / at risk     30/125 (24.00%)     35/124 (28.23%)     37/127 (29.13%)     30/127 (23.62%)  
Cataract cortical (F) † 1 [3]        
# participants affected / at risk     10/125 (8.00%)     3/124 (2.42%)     8/127 (6.30%)     6/127 (4.72%)  
Cataract cortical (S) † 1 [4]        
# participants affected / at risk     8/125 (6.40%)     5/124 (4.03%)     6/127 (4.72%)     7/127 (5.51%)  
Cataract nuclear (F) † 1 [3]        
# participants affected / at risk     10/125 (8.00%)     5/124 (4.03%)     2/127 (1.57%)     4/127 (3.15%)  
Cataract nuclear (S) † 1 [4]        
# participants affected / at risk     6/125 (4.80%)     8/124 (6.45%)     4/127 (3.15%)     5/127 (3.94%)  
Cataract subcapsular (F) † 1 [3]        
# participants affected / at risk     7/125 (5.60%)     8/124 (6.45%)     3/127 (2.36%)     3/127 (2.36%)  
Conjunctival haemorrhage (F) † 1 [3]        
# participants affected / at risk     8/125 (6.40%)     14/124 (11.29%)     11/127 (8.66%)     5/127 (3.94%)  
Conjunctival haemorrhage (S) † 1 [4]        
# participants affected / at risk     54/125 (43.20%)     63/124 (50.81%)     45/127 (35.43%)     40/127 (31.50%)  
Diabetic retinal oedema (F) † 1 [3]        
# participants affected / at risk     25/125 (20.00%)     16/124 (12.90%)     20/127 (15.75%)     18/127 (14.17%)  
Diabetic retinal oedema (S) † 1 [4]        
# participants affected / at risk     8/125 (6.40%)     3/124 (2.42%)     8/127 (6.30%)     8/127 (6.30%)  
Diabetic retinopathy (F) † 1 [3]        
# participants affected / at risk     8/125 (6.40%)     10/124 (8.06%)     5/127 (3.94%)     6/127 (4.72%)  
Dry eye (F) † 1 [3]        
# participants affected / at risk     4/125 (3.20%)     7/124 (5.65%)     10/127 (7.87%)     4/127 (3.15%)  
Dry eye (S) † 1 [4]        
# participants affected / at risk     7/125 (5.60%)     8/124 (6.45%)     8/127 (6.30%)     2/127 (1.57%)  
Eye irritation (S) † 1 [4]        
# participants affected / at risk     8/125 (6.40%)     7/124 (5.65%)     6/127 (4.72%)     4/127 (3.15%)  
Eye pain (S) † 1 [4]        
# participants affected / at risk     14/125 (11.20%)     18/124 (14.52%)     11/127 (8.66%)     9/127 (7.09%)  
Foreign body sensation in eyes (S) † 1 [4]        
# participants affected / at risk     10/125 (8.00%)     4/124 (3.23%)     8/127 (6.30%)     7/127 (5.51%)  
Lacrimation increased (S) † 1 [4]        
# participants affected / at risk     7/125 (5.60%)     5/124 (4.03%)     6/127 (4.72%)     3/127 (2.36%)  
Macular fibrosis (F) † 1 [3]        
# participants affected / at risk     12/125 (9.60%)     9/124 (7.26%)     6/127 (4.72%)     0/127 (0.00%)  
Macular fibrosis (S) † 1 [4]        
# participants affected / at risk     7/125 (5.60%)     8/124 (6.45%)     13/127 (10.24%)     0/127 (0.00%)  
Macular oedema (F) † 1 [3]        
# participants affected / at risk     46/125 (36.80%)     52/124 (41.94%)     37/127 (29.13%)     29/127 (22.83%)  
Macular oedema (S) † 1 [4]        
# participants affected / at risk     32/125 (25.60%)     25/124 (20.16%)     33/127 (25.98%)     26/127 (20.47%)  
Maculopathy (F) † 1 [3]        
# participants affected / at risk     2/125 (1.60%)     1/124 (0.81%)     4/127 (3.15%)     7/127 (5.51%)  
Maculopathy (S) † 1 [4]        
# participants affected / at risk     1/125 (0.80%)     0/124 (0.00%)     3/127 (2.36%)     10/127 (7.87%)  
Ocular hyperaemia (S) † 1 [4]        
# participants affected / at risk     5/125 (4.00%)     5/124 (4.03%)     10/127 (7.87%)     10/127 (7.87%)  
Posterior capsule opacification (S) † 1 [4]        
# participants affected / at risk     7/125 (5.60%)     5/124 (4.03%)     5/127 (3.94%)     4/127 (3.15%)  
Retinal exudates (F) † 1 [3]        
# participants affected / at risk     23/125 (18.40%)     21/124 (16.94%)     18/127 (14.17%)     15/127 (11.81%)  
Retinal exudates (S) † 1 [4]        
# participants affected / at risk     22/125 (17.60%)     20/124 (16.13%)     19/127 (14.96%)     14/127 (11.02%)  
Retinal haemorrhage (F) † 1 [3]        
# participants affected / at risk     32/125 (25.60%)     40/124 (32.26%)     31/127 (24.41%)     20/127 (15.75%)  
Retinal haemorrhage (S) † 1 [4]        
# participants affected / at risk     21/125 (16.80%)     34/124 (27.42%)     25/127 (19.69%)     23/127 (18.11%)  
Retinal neovascularisation (F) † 1 [3]        
# participants affected / at risk     13/125 (10.40%)     12/124 (9.68%)     13/127 (10.24%)     10/127 (7.87%)  
Retinal neovascularisation (S) † 1 [4]        
# participants affected / at risk     1/125 (0.80%)     1/124 (0.81%)     8/127 (6.30%)     7/127 (5.51%)  
Vision blurred (S) † 1 [4]        
# participants affected / at risk     10/125 (8.00%)     5/124 (4.03%)     5/127 (3.94%)     5/127 (3.94%)  
Vitreous detachment (F) † 1 [3]        
# participants affected / at risk     13/125 (10.40%)     12/124 (9.68%)     20/127 (15.75%)     19/127 (14.96%)  
Vitreous detachment (S) † 1 [4]        
# participants affected / at risk     14/125 (11.20%)     22/124 (17.74%)     22/127 (17.32%)     19/127 (14.96%)  
Vitreous floaters (F) † 1 [3]        
# participants affected / at risk     3/125 (2.40%)     6/124 (4.84%)     8/127 (6.30%)     7/127 (5.51%)  
Vitreous floaters (S) † 1 [4]        
# participants affected / at risk     10/125 (8.00%)     13/124 (10.48%)     6/127 (4.72%)     4/127 (3.15%)  
Vitreous haemorrhage (F) † 1 [3]        
# participants affected / at risk     17/125 (13.60%)     14/124 (11.29%)     16/127 (12.60%)     12/127 (9.45%)  
Vitreous haemorrhage (S) † 1 [4]        
# participants affected / at risk     3/125 (2.40%)     4/124 (3.23%)     17/127 (13.39%)     17/127 (13.39%)  
Gastrointestinal disorders          
Constipation † 1        
# participants affected / at risk     14/125 (11.20%)     9/124 (7.26%)     9/127 (7.09%)     7/127 (5.51%)  
Diarrhoea † 1        
# participants affected / at risk     3/125 (2.40%)     11/124 (8.87%)     6/127 (4.72%)     6/127 (4.72%)  
Gastrooesophageal reflux disease † 1        
# participants affected / at risk     6/125 (4.80%)     10/124 (8.06%)     6/127 (4.72%)     6/127 (4.72%)  
Nausea † 1        
# participants affected / at risk     14/125 (11.20%)     9/124 (7.26%)     15/127 (11.81%)     13/127 (10.24%)  
Vomiting † 1        
# participants affected / at risk     6/125 (4.80%)     7/124 (5.65%)     10/127 (7.87%)     9/127 (7.09%)  
General disorders          
Oedema peripheral † 1        
# participants affected / at risk     9/125 (7.20%)     7/124 (5.65%)     4/127 (3.15%)     5/127 (3.94%)  
Immune system disorders          
Drug hypersensitivity † 1        
# participants affected / at risk     2/125 (1.60%)     1/124 (0.81%)     7/127 (5.51%)     6/127 (4.72%)  
Seasonal allergy † 1        
# participants affected / at risk     12/125 (9.60%)     9/124 (7.26%)     6/127 (4.72%)     5/127 (3.94%)  
Infections and infestations          
Bronchitis † 1        
# participants affected / at risk     8/125 (6.40%)     12/124 (9.68%)     6/127 (4.72%)     5/127 (3.94%)  
Cellulitis † 1        
# participants affected / at risk     5/125 (4.00%)     3/124 (2.42%)     9/127 (7.09%)     4/127 (3.15%)  
Influenza † 1        
# participants affected / at risk     10/125 (8.00%)     13/124 (10.48%)     9/127 (7.09%)     7/127 (5.51%)  
Nasopharyngitis † 1        
# participants affected / at risk     16/125 (12.80%)     13/124 (10.48%)     10/127 (7.87%)     6/127 (4.72%)  
Pneumonia † 1        
# participants affected / at risk     5/125 (4.00%)     8/124 (6.45%)     6/127 (4.72%)     4/127 (3.15%)  
Sinusitis † 1        
# participants affected / at risk     9/125 (7.20%)     14/124 (11.29%)     14/127 (11.02%)     12/127 (9.45%)  
Upper respiratory tract infection † 1        
# participants affected / at risk     12/125 (9.60%)     13/124 (10.48%)     14/127 (11.02%)     12/127 (9.45%)  
Urinary tract infection † 1        
# participants affected / at risk     13/125 (10.40%)     17/124 (13.71%)     24/127 (18.90%)     19/127 (14.96%)  
Injury, poisoning and procedural complications          
Corneal abrasion (S) † 1 [4]        
# participants affected / at risk     7/125 (5.60%)     4/124 (3.23%)     8/127 (6.30%)     6/127 (4.72%)  
Fall † 1        
# participants affected / at risk     10/125 (8.00%)     2/124 (1.61%)     8/127 (6.30%)     3/127 (2.36%)  
Procedural pain † 1        
# participants affected / at risk     1/125 (0.80%)     7/124 (5.65%)     3/127 (2.36%)     1/127 (0.79%)  
Investigations          
Blood creatinine increased † 1        
# participants affected / at risk     7/125 (5.60%)     5/124 (4.03%)     6/127 (4.72%)     6/127 (4.72%)  
Blood glucose increased † 1        
# participants affected / at risk     10/125 (8.00%)     9/124 (7.26%)     9/127 (7.09%)     8/127 (6.30%)  
Intraocular pressure increased (F) † 1 [3]        
# participants affected / at risk     7/125 (5.60%)     12/124 (9.68%)     7/127 (5.51%)     6/127 (4.72%)  
Intraocular pressure increased (S) † 1 [4]        
# participants affected / at risk     20/125 (16.00%)     25/124 (20.16%)     17/127 (13.39%)     14/127 (11.02%)  
Metabolism and nutrition disorders          
Diabetes mellitus † 1        
# participants affected / at risk     18/125 (14.40%)     18/124 (14.52%)     23/127 (18.11%)     20/127 (15.75%)  
Hypercholesterolaemia † 1        
# participants affected / at risk     12/125 (9.60%)     3/124 (2.42%)     6/127 (4.72%)     5/127 (3.94%)  
Hyperkalaemia † 1        
# participants affected / at risk     5/125 (4.00%)     8/124 (6.45%)     4/127 (3.15%)     4/127 (3.15%)  
Hyperlipidaemia † 1        
# participants affected / at risk     7/125 (5.60%)     2/124 (1.61%)     2/127 (1.57%)     2/127 (1.57%)  
Hypoglycaemia † 1        
# participants affected / at risk     5/125 (4.00%)     2/124 (1.61%)     7/127 (5.51%)     6/127 (4.72%)  
Musculoskeletal and connective tissue disorders          
Back pain † 1        
# participants affected / at risk     5/125 (4.00%)     8/124 (6.45%)     13/127 (10.24%)     10/127 (7.87%)  
Nervous system disorders          
Diabetic neuropathy † 1        
# participants affected / at risk     7/125 (5.60%)     1/124 (0.81%)     6/127 (4.72%)     4/127 (3.15%)  
Dizziness † 1        
# participants affected / at risk     5/125 (4.00%)     7/124 (5.65%)     5/127 (3.94%)     4/127 (3.15%)  
Headache † 1        
# participants affected / at risk     10/125 (8.00%)     7/124 (5.65%)     10/127 (7.87%)     7/127 (5.51%)  
Neuropathy peripheral † 1        
# participants affected / at risk     7/125 (5.60%)     3/124 (2.42%)     5/127 (3.94%)     4/127 (3.15%)  
Psychiatric disorders          
Anxiety † 1        
# participants affected / at risk     6/125 (4.80%)     3/124 (2.42%)     8/127 (6.30%)     7/127 (5.51%)  
Renal and urinary disorders          
Renal failure † 1        
# participants affected / at risk     5/125 (4.00%)     12/124 (9.68%)     7/127 (5.51%)     6/127 (4.72%)  
Respiratory, thoracic and mediastinal disorders          
Cough † 1        
# participants affected / at risk     17/125 (13.60%)     10/124 (8.06%)     10/127 (7.87%)     8/127 (6.30%)  
Dyspnoea † 1        
# participants affected / at risk     3/125 (2.40%)     1/124 (0.81%)     8/127 (6.30%)     7/127 (5.51%)  
Skin and subcutaneous tissue disorders          
Skin ulcer † 1        
# participants affected / at risk     2/125 (1.60%)     5/124 (4.03%)     7/127 (5.51%)     3/127 (2.36%)  
Vascular disorders          
Hypertension † 1        
# participants affected / at risk     32/125 (25.60%)     34/124 (27.42%)     31/127 (24.41%)     27/127 (21.26%)  
Events were collected by systematic assessment
1 Term from vocabulary, MedDRA (13.1)
[3] (F)=fellow eye
[4] (S)=study eye



  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Medical Communications
Organization: Genentech, Inc.
phone: 800 821-8590


No publications provided by Genentech

Publications automatically indexed to this study:

Responsible Party: Genentech
ClinicalTrials.gov Identifier: NCT00473382     History of Changes
Other Study ID Numbers: FVF4168g
Study First Received: May 13, 2007
Results First Received: November 30, 2012
Last Updated: August 1, 2013
Health Authority: United States: Food and Drug Administration